Avadel Pharmaceuticals plc announced the appointment of Thomas S. McHugh as its new Chief Financial Officer, replacing Michael Kanan, effective immediately. In addition, the company has appointed Dr. Jason M. Vaughn to the newly formed role of Senior Vice President of Technical Operations, where his responsibilities will include overseeing the analytical, process development, technical transfer and commercial scale up of the company's lead clinical program, FT218. These two appointments bring significant financial and operational experience in the biopharmaceutical industry to Avadel.

Mr. McHugh and Dr. Vaughn will report to Avadel's Chief Executive Officer, Greg Divis. Mr. McHugh most recently served as Senior Vice President of Finance of Ironshore Pharmaceuticals Inc. Dr. Vaughn has held several executive and managerial roles throughout his career. Before joining Avadel, Dr. Vaughn was Principal at Wyatt Pharma Consulting, LLC where he led several development programs for client companies, including Avadel.